The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

Shares of XOMA Royalty (XOMA) have gained 22.2% over the past four weeks to close the last trading session at $31.37, but ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announ ...

XOMA Royalty adds milestone and royalty economics associated with two partnered assets News provided by XOMA Royalty Corporation; LAVA Therapeutics N.V. Aug 04, 2025, 7:30 AM ET ...

XOMA Royalty Corporation has announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Cumulative Preferred Stock, payable on or about January 15 ...

When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate (s) or for general corporate purposes.